The abstract is read at the publisher; the summary is JClub's.
A post hoc model for ANCA-associated vasculitis in 649 PEXIVAS trial participants predicts 2-year first relapse risk, with optimism-corrected AUC 0.709 (95% CI 0.707–0.710).
- Why it matters: Relapse risk varies across individuals with ANCA-associated vasculitis, but clinicians need individualized 2-year risk estimates to guide monitoring and treatment after remission.
- What they did: Using trial participants who achieved remission and had eGFR <50 mL/min/1.73 m2 or diffuse alveolar haemorrhage, the study selected predictors via LASSO time-to-event methods and assessed stability and calibration.
- The result: Among 649 participants, 100 relapsed within 2 years, and the final model used sex, induction agent (oral cyclophosphamide or rituximab), ANCA subtype, specific involvement at presentation, and eGFR at remission, with calibration slope 0.99 (95% CI 0.65–1.34).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.